Literature DB >> 2982382

Irreversible inactivation of rat gastric (H+-K+)-ATPase in vivo by omeprazole.

W B Im, D P Blakeman, J P Davis.   

Abstract

Subcutaneous administration of omeprazole, a gastric antisecretory agent belonging to the family of substituted benzimidazoles, brought about a dose-dependent decrease in gastric mucosal (H+-K+)-ATPase activity in the rat. The dose which inhibited 50% of the enzyme activity was 1 mg/kg from dose-response profiles obtained 3 h after the drug dosing. Duration profiles of the drug at 10 mg/kg showed that its ATPase-inhibitory effect reached the maximum in 2 h with 80% reduction of the enzyme activity. The gastric mucosal level of the ATPase activity remained to be maximally inhibited for 12 h and returned to a normal level with a half time of about 20 h. The return of the enzyme activity, however, was blocked by treatment with cycloheximide, an inhibitor of protein synthesis. These observations indicate that omeprazole irreversibly inactivates gastric (H+-K+)-ATPase in vivo.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2982382     DOI: 10.1016/0006-291x(85)90573-x

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  13 in total

1.  Acid suppression.

Authors:  R H Hunt
Journal:  BMJ       Date:  1990-11-03

Review 2.  Molecular mechanisms in therapy of acid-related diseases.

Authors:  J M Shin; O Vagin; K Munson; M Kidd; I M Modlin; G Sachs
Journal:  Cell Mol Life Sci       Date:  2008-01       Impact factor: 9.261

3.  Omeprazole suppressed plasma magnesium level and duodenal magnesium absorption in male Sprague-Dawley rats.

Authors:  Narongrit Thongon; Jirawat Penguy; Sasikan Kulwong; Kanyanat Khongmueang; Matthana Thongma
Journal:  Pflugers Arch       Date:  2016-11-19       Impact factor: 3.657

4.  Effect of potent urease inhibitor, fluorofamide, on Helicobacter sp. in vivo and in vitro.

Authors:  A J Pope; C D Toseland; B Rushant; S Richardson; M McVey; J Hills
Journal:  Dig Dis Sci       Date:  1998-01       Impact factor: 3.199

Review 5.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

6.  Famotidine, a histamine-2-receptor antagonist, inhibits the increase in rat gastric H+/K(+)-ATPase mRNA induced by intravenous infusion of gastrin 17 and histamine.

Authors:  G Yamamoto; A Tari; K Sumii; M Sumii; K Haruma; G Kajiyama
Journal:  Dig Dis Sci       Date:  1995-09       Impact factor: 3.199

Review 7.  Lansoprazole. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders.

Authors:  L B Barradell; D Faulds; D McTavish
Journal:  Drugs       Date:  1992-08       Impact factor: 9.546

Review 8.  The gastric HK-ATPase: structure, function, and inhibition.

Authors:  Jai Moo Shin; Keith Munson; Olga Vagin; George Sachs
Journal:  Pflugers Arch       Date:  2008-06-06       Impact factor: 3.657

Review 9.  Pharmacological aspects of acid secretion.

Authors:  B I Hirschowitz; D Keeling; M Lewin; S Okabe; M Parsons; K Sewing; B Wallmark; G Sachs
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

Review 10.  Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders.

Authors:  W Creutzfeldt
Journal:  Drug Saf       Date:  1994-01       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.